表紙
市場調查報告書
商品編碼
1063702

腎上腺腦白質營養不良治療的全球市場:產業分析,趨勢,市場規模,2027年前的預測

Adrenoleukodystrophy Treatment Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2027

出版日期: | 出版商: Infinium Global Research (IGR) | 英文 100 Pages | 商品交期: 最快1-2個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球腎上腺腦白質營養不良治療的市場規模在預測期間內預計將以12%的年複合成長率增長。

這份報告提供全球腎上腺腦白質營養不良治療市場調查,提供市場預測和概要,市場的推動因素與阻礙因素的分析,COVID-19影響,不同治療,各類型,各地區的市場分析,競爭情形,主要企業的簡介等系統性資訊。

目錄

第1章 序文

  • 報告的說明
  • 調查方法
  • 研究途徑

第2章 摘要整理

  • 市場概況
  • 市場預測
  • 市場地區的亮點

第3章 全球腎上腺腦白質營養不良治療市場:概要

  • 簡介
  • 市場動態
    • 促進因素
    • 阻礙因素
    • 市場機會
  • COVID-19對市場的影響分析
  • 波特的五力分析
  • IGR-成長矩陣分析
    • 不同治療
    • 各類型
    • 各地區
  • 市場價值鏈分析

第4章 腎上腺腦白質營養不良治療市場:宏觀指標分析

第5章 全球腎上腺腦白質營養不良治療市場:不同治療

  • 幹細胞移植
  • 基因治療
  • 皮質類固醇補充療法
  • 藥物
  • 其他

第6章 全球腎上腺腦白質營養不良治療藥市場:各類型

  • 兒童腦ALD
  • 腎上腺脊髓型頸椎病變
  • 愛迪生氏病

第7章 全球腎上腺腦白質營養不良治療市場(2021年∼2027年):各地區

  • 北美
    • 不同治療
    • 各類型
    • 各國
  • 歐洲
    • 不同治療
    • 各類型
    • 各國
  • 亞太地區
    • 不同治療
    • 各類型
    • 各國
  • 其他地區
    • 不同治療
    • 各類型
    • 各子地區

第8章 企業簡介和競爭情形

  • 競爭情形
  • 企業簡介
    • ALD Connect
    • MedDay Pharmaceuticals
    • Bluebird bio, Inc
    • AstraZeneca
    • Abbott
    • ReceptoPharm, Inc
    • Nutra Pharma Corporation
    • Genetix Biotech Asia Pvt. Ltd
    • Novartis AG
    • Jazz Pharmaceuticals, Inc
目錄
Product Code: HC08743

The report on the global adrenoleukodystrophy treatment market provides qualitative and quantitative analysis for the period from 2019 to 2027. The report predicts the global adrenoleukodystrophy treatment market to grow with a CAGR of 12% over the forecast period from 2021-2027. The study on adrenoleukodystrophy treatment market covers the analysis of the leading geographies such as North America, Europe, Asia-Pacific, and RoW for the period of 2019 to 2027.

The report on adrenoleukodystrophy treatment market is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global adrenoleukodystrophy treatment market over the period of 2019 to 2027. Moreover, the report is a collective presentation of primary and secondary research findings.

Porter's five forces model in the report provides insights into the competitive rivalry, supplier and buyer positions in the market and opportunities for the new entrants in the global adrenoleukodystrophy treatment market over the period of 2019 to 2027. Further, IGR- Growth Matrix gave in the report brings an insight into the investment areas that existing or new market players can consider.

Report Findings

1) Drivers

  • Rising financial support for research into new ALD treatments will contribute to driving forces in the market growth

2) Restraints

  • The side-effects associated with stem cell therapy and corticosteroid as there is no as such treatment proved for this disease can hamper the growth in the market

3) Opportunities

  • Major investment activities by the government in the developing countries in order to improve the best infrastructure can lead to an increase of patient assessment can create an opportunity for its market growth in upcoming years

Research Methodology

A) Primary Research

Our primary research involves extensive interviews and analysis of the opinions provided by the primary respondents. The primary research starts with identifying and approaching the primary respondents, the primary respondents are approached include

  • 1. Key Opinion Leaders associated with Infinium Global Research
  • 2. Internal and External subject matter experts
  • 3. Professionals and participants from the industry

Our primary research respondents typically include

  • 1. Executives working with leading companies in the market under review
  • 2. Product/brand/marketing managers
  • 3. CXO level executives
  • 4. Regional/zonal/ country managers
  • 5. Vice President level executives.

B) Secondary Research

Secondary research involves extensive exploring through the secondary sources of information available in both the public domain and paid sources. At Infinium Global Research, each research study is based on over 500 hours of secondary research accompanied by primary research. The information obtained through the secondary sources is validated through the crosscheck on various data sources.

The secondary sources of the data typically include

  • 1. Company reports and publications
  • 2. Government/institutional publications
  • 3. Trade and associations journals
  • 4. Databases such as WTO, OECD, World Bank, and among others.
  • 5. Websites and publications by research agencies

Segment Covered

The global adrenoleukodystrophy treatment market is segmented on the basis of therapy, and type.

The Global Adrenoleukodystrophy Treatment Market by Therapy

  • Stem Cell Transplant
  • Gene Therapy
  • Corticosteroid Replacement Therapy
  • Medications
  • Others

The Global Adrenoleukodystrophy Treatment Market by Type

  • Childhood Cerebral ALD
  • Adrenomyelopathy
  • Addison's Disease

Company Profiles

The companies covered in the report include

  • ALD Connect
  • MedDay Pharmaceuticals
  • Bluebird bio, Inc
  • AstraZeneca
  • Abbott
  • ReceptoPharm, Inc
  • Nutra Pharma Corporation
  • Genetix Biotech Asia Pvt. Ltd
  • Novartis AG
  • Jazz Pharmaceuticals, Inc

What does this Report Deliver?

1. Comprehensive analysis of the global as well as regional markets of the adrenoleukodystrophy treatment market.

2. Complete coverage of all the segments in the adrenoleukodystrophy treatment market to analyze the trends, developments in the global market and forecast of market size up to 2027.

3. Comprehensive analysis of the companies operating in the global adrenoleukodystrophy treatment market. The company profile includes analysis of product portfolio, revenue, SWOT analysis and latest developments of the company.

4. IGR- Growth Matrix presents an analysis of the product segments and geographies that market players should focus to invest, consolidate, expand and/or diversify.

Table of Contents

1. Preface

  • 1.1. Report Description
  • 1.2. Research Methods
  • 1.3. Research Approaches

2. Executive Summary

  • 2.1. Adrenoleukodystrophy Treatment Market Highlights
  • 2.2. Adrenoleukodystrophy Treatment Market Projection
  • 2.3. Adrenoleukodystrophy Treatment Market Regional Highlights

3. Global Adrenoleukodystrophy Treatment Market Overview

  • 3.1. Introduction
  • 3.2. Market Dynamics
    • 3.2.1. Drivers
    • 3.2.2. Restraints
    • 3.2.3. Opportunities
  • 3.3. Analysis of COVID-19 impact on the Adrenoleukodystrophy Treatment Market
  • 3.4. Porter's Five Forces Analysis
  • 3.5. IGR-Growth Matrix Analysis
    • 3.5.1. IGR-Growth Matrix Analysis by Therapy
    • 3.5.2. IGR-Growth Matrix Analysis by Type
    • 3.5.3. IGR-Growth Matrix Analysis by Region
  • 3.6. Value Chain Analysis of Adrenoleukodystrophy Treatment Market

4. Adrenoleukodystrophy Treatment Market Macro Indicator Analysis

5. Global Adrenoleukodystrophy Treatment Market by Therapy

  • 5.1. Stem Cell Transplant
  • 5.2. Gene Therapy
  • 5.3. Corticosteroid Replacement Therapy
  • 5.4. Medications
  • 5.5. Others

6. Global Adrenoleukodystrophy Treatment Market by Type

  • 6.1. Childhood Cerebral ALD
  • 6.2. Adrenomyelopathy
  • 6.3. Addison's Disease

7. Global Adrenoleukodystrophy Treatment Market by Region 2021-2027

  • 7.1. North America
    • 7.1.1. North America Adrenoleukodystrophy Treatment Market by Therapy
    • 7.1.2. North America Adrenoleukodystrophy Treatment Market by Type
    • 7.1.3. North America Adrenoleukodystrophy Treatment Market by Country
  • 7.2. Europe
    • 7.2.1. Europe Adrenoleukodystrophy Treatment Market by Therapy
    • 7.2.2. Europe Adrenoleukodystrophy Treatment Market by Type
    • 7.2.3. Europe Adrenoleukodystrophy Treatment Market by Country
  • 7.3. Asia-Pacific
    • 7.3.1. Asia-Pacific Adrenoleukodystrophy Treatment Market by Therapy
    • 7.3.2. Asia-Pacific Adrenoleukodystrophy Treatment Market by Type
    • 7.3.3. Asia-Pacific Adrenoleukodystrophy Treatment Market by Country
  • 7.4. RoW
    • 7.4.1. RoW Adrenoleukodystrophy Treatment Market by Therapy
    • 7.4.2. RoW Adrenoleukodystrophy Treatment Market by Type
    • 7.4.3. RoW Adrenoleukodystrophy Treatment Market by Sub-region

8. Company Profiles and Competitive Landscape

  • 8.1. Competitive Landscape in the Global Adrenoleukodystrophy Treatment Market
  • 8.2. Companies Profiles
    • 8.2.1. ALD Connect
    • 8.2.2. MedDay Pharmaceuticals
    • 8.2.3. Bluebird bio, Inc
    • 8.2.4. AstraZeneca
    • 8.2.5. Abbott
    • 8.2.6. ReceptoPharm, Inc
    • 8.2.7. Nutra Pharma Corporation
    • 8.2.8. Genetix Biotech Asia Pvt. Ltd
    • 8.2.9. Novartis AG
    • 8.2.10. Jazz Pharmaceuticals, Inc